Lion Biotechnologies Inc (NASDAQ:LBIO)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued to investors on Wednesday.

Several other analysts also recently weighed in on LBIO. Zacks Investment Research raised shares of Lion Biotechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, January 17th. Roth Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Wednesday, February 15th. Jefferies Group LLC dropped their target price on shares of Lion Biotechnologies from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, March 8th. FBR & Co set a $17.00 target price on shares of Lion Biotechnologies and gave the stock a “buy” rating in a research report on Wednesday, March 8th. Finally, Wells Fargo & Co started coverage on shares of Lion Biotechnologies in a research report on Friday, March 17th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.29.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:LBIO)

Lion Biotechnologies (NASDAQ:LBIO) opened at 5.80 on Wednesday. The company’s market cap is $361.64 million. Lion Biotechnologies has a 12 month low of $5.48 and a 12 month high of $9.58. The company’s 50-day moving average is $6.41 and its 200-day moving average is $6.97.

Lion Biotechnologies (NASDAQ:LBIO) last issued its quarterly earnings data on Monday, May 1st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.05. On average, equities research analysts expect that Lion Biotechnologies will post ($1.39) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Chardan Capital Reiterates “Buy” Rating for Lion Biotechnologies Inc (LBIO)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/20/chardan-capital-reiterates-buy-rating-for-lion-biotechnologies-inc-lbio.html.

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new stake in Lion Biotechnologies during the second quarter valued at $151,000. Quantitative Systematic Strategies LLC bought a new stake in Lion Biotechnologies during the second quarter valued at $178,000. Bank of New York Mellon Corp increased its stake in Lion Biotechnologies by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 183,631 shares of the biotechnology company’s stock valued at $1,488,000 after buying an additional 5,001 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in Lion Biotechnologies during the second quarter valued at $117,000. Finally, Emerald Acquisition Ltd. bought a new stake in Lion Biotechnologies during the second quarter valued at $327,000. 75.97% of the stock is currently owned by institutional investors.

About Lion Biotechnologies

Lion Biotechnologies, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

12 Month Chart for NASDAQ:LBIO

Receive News & Ratings for Lion Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.